SCHEMBL1637247

SCHEMBL1637247

O=C(N/N=C\c1cc(F)cc(F)c1O)c1ccccc1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.66
KMT2A Q03164 7/20 0.66
KDM4E B2RXH2 4/20 0.66
MAPK1 P28482 3/20 0.66
TDP1 Q9NUW8 2/20 0.66
TP53 P04637 1/20 0.66
CYP3A4 P08684 1/20 0.66
CYP2D6 P10635 1/20 0.66
HPGD P15428 1/20 0.66
HSD17B10 Q99714 1/20 0.66
NTRK1 P04629 3/20 0.64
ALOX5 P09917 1/20 0.59
PTGS2 P35354 1/20 0.59
NPSR1 Q6W5P4 1/20 0.55
RAB9A P51151 4/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
PIK3CG P48736 1/20 0.53
MAPT P10636 5/20 0.53
HTT P42858 4/20 0.53
NPC1 O15118 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1637249 1.00 MEN1 (0.66) MEN1KMT2AKDM4EMAPK1TDP1
SCHEMBL12766748 1.00 MEN1 (0.66) MEN1KMT2AKDM4EMAPK1TDP1
SCHEMBL685298 0.89 KMT2A (0.61) MEN1KMT2AKDM4EMAPK1TDP1
SCHEMBL1638434 0.87 KMT2A (0.63) MEN1KMT2AKDM4EMAPK1TDP1
SCHEMBL12766766 0.87 KMT2A (0.63) MEN1KMT2AKDM4EMAPK1TDP1
SCHEMBL1638436 0.87 KMT2A (0.63) MEN1KMT2AKDM4EMAPK1TDP1
SCHEMBL1638609 0.85 MEN1 (0.72) MEN1KMT2AKDM4EMAPK1TDP1
SCHEMBL1638612 0.85 MEN1 (0.72) MEN1KMT2AKDM4EMAPK1TDP1
SCHEMBL12767331 0.85 MEN1 (0.72) MEN1KMT2AKDM4EMAPK1TDP1
SCHEMBL1639164 0.81 PIK3CG (0.72) MEN1KMT2AKDM4EMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US claimed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP claimed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO claimed
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP disclosed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 MEN1 2974/4885KMT2A 3625/4885KDM4E 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.